May 21, 2012 — Minnetronix announced the exclusive licensing rights of Penn State Research Foundation’s wireless energy transmission technology to power circulatory assist devices in the treatment of congestive heart failure. Wireless energy transmission technology enables therapies for congestive heart failure, such as left ventricular assist devices (LVAD), to become fully implantable. Penn State is one of only two organizations in the world to have developed and deployed such a system clinically.
Minnetronix, a Minnesota-based medical device design and manufacturing firm, first began work with Penn State/Hershey Medical Center in 1996 as the two organizations collaborated in the development of the electric total artificial heart, intended for patients with end-stage heart disease.
With a 16-year history in the field of mechanical circulatory support, as well as a variety of other Class II and III technologies, Minnetronix looks forward to bringing its first proprietary medical technology to the marketplace to help achieve its mission of developing and enhancing patient outcomes.
The Penn State wireless energy transmission technology will consist of a more mobile and fully implantable system which will benefit clinicians and patients alike.
The first application is expected to be introduced within the LVAD market space. The next steps are preclinical and clinical testing and development.
For more information: www.minnetronix.com
June 19, 2024 
